Volatility and then swift upswing indicates a buyout. However, since Clay went onto CNBC to tout the company's marketed drug Adcetris and its pipeline in all sorts of cancer, seems to me he is playin ghard ball with the potential suiters. If he thought the offers were serious enough and they were in "real" negotiation then I doubt he would be out there in CNBC and giving that kind of interview. With the Eu approval looming and sales number to be reported next month, I don;t think he will take any offer below #40 to be at all serious. I think he is holding out for more than $50 offer to even consider. he has seem what can happen vis a vis MITI MEDX etc.